Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva's Copaxone Continues To Widen MS Market Lead In U.S.

Executive Summary

The multiple sclerosis market underwent a shake-out in 2008 when Teva's Copaxone managed to pull ahead of more established beta interferon therapies, including Biogen Idec's Avonex; the drug now holds 38 percent of the nearly $4.5 billion U.S. market

You may also be interested in...



Follow-on Biologic's Day Will Come - Post 2015, Teva Says

The generic giant acknowledges biogenerics as a major growth driver, but probably not before 2015.

The New Oral MS Drugs: The Challenges in Dislodging Biologics

Oral replacements for injectable drugs have long been an industry aspiration. The complex issues riased by the first oral MS drugs, as they try to take over territory pioneered by large molecules, reveal the challenges for companies pursuing other biologic-dominated businesses.

The New Oral MS Drugs: The Challenges in Dislodging Biologics

Oral replacements for injectable drugs have long been an industry aspiration. The complex issues riased by the first oral MS drugs, as they try to take over territory pioneered by large molecules, reveal the challenges for companies pursuing other biologic-dominated businesses.

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel